Patents by Inventor Anders Mattson
Anders Mattson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8466175Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: November 17, 2011Date of Patent: June 18, 2013Assignee: AstraZeneca ABInventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
-
Publication number: 20120252847Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: ApplicationFiled: November 17, 2011Publication date: October 4, 2012Inventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Mõller
-
Patent number: 8076361Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2 -pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: May 21, 2010Date of Patent: December 13, 2011Assignee: AstraZeneca ABInventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
-
Publication number: 20110130570Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2 -pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: ApplicationFiled: May 21, 2010Publication date: June 2, 2011Inventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Mõller
-
Patent number: 7745466Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: September 11, 2007Date of Patent: June 29, 2010Assignee: AstraZeneca ABInventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
-
Publication number: 20080255363Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: ApplicationFiled: September 11, 2007Publication date: October 16, 2008Inventors: Hanna Cotton, Anders Kronstrom, Anders Mattson, Eva Moller
-
Patent number: 7411070Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: September 25, 2003Date of Patent: August 12, 2008Assignee: AstraZeneca ABInventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
-
Publication number: 20050075369Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: ApplicationFiled: September 25, 2003Publication date: April 7, 2005Inventors: Hanna Cotton, Anders Kronstrom, Anders Mattson, Eva Moller
-
Patent number: 6747155Abstract: The present invention relates to a novel process for the preparation of the magnesium salt of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole trihydrate, i.e. S-omeprazole magnesium salt trihydrate. The present invention also relates to the S-omeprazole magnesium salt trihydrate prepared in accordance with the new process and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: April 1, 2002Date of Patent: June 8, 2004Assignee: AstraZeneca ABInventors: Anders Kronström, Eva Leander, Anders Mattson, Karin Jansson, Martin Bohlin
-
Patent number: 6677455Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: February 14, 2002Date of Patent: January 13, 2004Assignee: AstraZeneca ABInventors: Anders Kronström, Eva Leander, Anders Mattson
-
Publication number: 20030004190Abstract: The present invention relates to a novel process for the preparation of the magnesium salt of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole trihydrate, ie. S-omeprazole magnesium salt trihydrate. The present invention also relates to the S-omeprazole magnesium salt trihydrate prepared in accordance with the new process and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: ApplicationFiled: April 1, 2002Publication date: January 2, 2003Inventors: Anders Kronstrom, Eva Leander, Anders Mattson, Karin Jansson, Martin Bohlin
-
Publication number: 20020198239Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: ApplicationFiled: February 14, 2002Publication date: December 26, 2002Inventors: Anders Kronstrom, Eva Leander, Anders Mattson
-
Patent number: 6369085Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: June 8, 1998Date of Patent: April 9, 2002Assignee: AstraZeneca ABInventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
-
Patent number: 6350877Abstract: A method for the manufacture of clevidipine by reaction of an inorganic salt of 4-(2′,3′-dichlorophenyl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridine-carboxylate and chloro methyl butyrate.Type: GrantFiled: March 8, 2000Date of Patent: February 26, 2002Assignee: AstraZeneca ABInventors: Anders Mattson, Carina Svensson, Karin Thörnblom, Christina Ödman
-
Patent number: 6303788Abstract: The present invention relates to a novel process for the synthesis of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Moreover, the present invention also relates to manufacture of a pharmaceutical preparation thereof and its use in medicine. The novel process for the preparation of omeprazole, comprises the step of oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole in an organic solvent with an oxidizing agent in the presence of a titanium complex and optionally in the presence of a base.Type: GrantFiled: December 1, 1998Date of Patent: October 16, 2001Assignee: AstraZeneca ABInventors: Hanna Cotton, Magnus Larsson, Anders Mattson
-
Patent number: 6124464Abstract: A novel process for the preparation of a magnesium salt of Formula I of a substituted sulfinyl heterocyclic compound containing an imidazole moiety. The process is carried out by mixing the substituted heterocycle of formula I with a weak and a magnesium source. The base and the magnesium source are selected to result in residues which are easy to remove during the reaction. The invention also relates to the use of the produced compounds in medicine.Type: GrantFiled: July 10, 1997Date of Patent: September 26, 2000Assignee: Astra AktiebolagInventors: Jan-.ANG.ke Hogberg, Panagiotis Ioannidis, Anders Mattson